# Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

> **NCT04406623** · PHASE1 · COMPLETED · sponsor: **Shattuck Labs, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** SL-172154

## Key facts

- **NCT ID:** NCT04406623
- **Lead sponsor:** Shattuck Labs, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-29
- **Primary completion:** 2023-02-02
- **Final completion:** 2023-02-02
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04406623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04406623, "Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04406623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*